The Role of Red Flavonoid in Photoaging

Skin Aging Clinical Trial

Official title:

The Role of Red Flavonoid in Photoaging

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05854628
• Other study ID #: IRB00384338
• Status: Withdrawn
• Phase: N/A
• Start date: October 2023
• Est. completion date: May 2025

Study information

• Verified date: December 2023
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about the effects of "red flavonoid" substance on skin, which is extracted from a plant called Camellia japonica, in adults aged of 45 or older with photo-damaged skin. The main questions it aims to answer are: - Does red flavonoid have an anti-aging effect? - Does red flavonoid have any skin quality-improving effects? Participants will - Be using creams with or without red flavonoid (only moisturizing creams) and sun-screen for the duration of the study. - Get a skin biopsy before and after using the creams. - Be taken photos of the face and neck region and have a skin examination at each visit. - Complete a self-questionnaire at final visit. Researchers will compare the group who uses red flavonoid facial cream with the group who uses moisturizing cream to see if red flavonoid has an effect on appearance and structure.

Description:

The purpose of this study is to investigate the anti-photoaging effects of red flavonoid, a product with natural phytochemical kaempferol tetrasaccharides (KTs) extracted from Camellia japonica. The investigators hypothesize that Red flavonoids extracted from Camellia japonica will present anti-aging effects, such as skin smoothening, increased elasticity, and brightening, with high subjective participant satisfaction and microscopically corroborating analyses. Individuals will be recruited from patient populations seen at the general dermatology clinics of Johns Hopkins Department of Dermatology or from patient populations participating in Johns Hopkins Cutaneous Translational Research Program (CTReP) research studies. Study procedures will be conducted at the Johns Hopkins CTReP office located at the Johns Hopkins Outpatient Center. Once eligibility has been demonstrated, the potential subjects will be instructed to make the first study appointment. This feasibility study will have a study population of up to 75 individuals over the age of 45. Each study participant will have up to 7 on-site visits within 24 weeks. A facial cream with or without 0.1% red flavonoid will be provided for twice-daily use. At various time points, photographs and clinical assessments will be collected as well as punch biopsy samples for laboratory study. At the discretion of the principal investigator, biopsies may be taken from subjects before and following daily usage of the product of interest, up to 8 biopsies in total. The timepoints may be adjusted as data is being collected. A punch biopsy procedure will be employed which is a routine dermatological procedure consisting of local anesthesia, followed by the punch, which cuts a cylindrical core of epidermis, dermis, and subcutaneous tissue. A biopsy size of up to 4-mm in diameter is considered enough to perform all tests required by this protocol. After removal of the tissue sample, a suture is placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin. Standardized digital photographs will be obtained by study staff using a digital camera and software under standard photographic conditions at each study visit. Participants' eyes will be blacked out to de-identify photos. Photograph files will be coded to remove personal identifiers and stored on a secure hard drive in CTReP. Non-invasive clinical assessments will be performed to 1) record skin findings using graded scales if needed, 2) to identify suitable areas for biopsy, 3) give information/demonstration about the product of interest, 4) to identify occurrence of any adverse events and 5) record post treatment findings. Tissue work-up may include, but not limited to hematoxylin and eosin staining for assessment of epidermal/dermal thickness, reverse transcription-polymerase chain reaction and immunohistochemistry for photoaging and pigmentation markers such as fibrillin-1, collagen type IV, or collagen type I, and tyrosinase. Any clinical findings determined by the Investigator to be important and/or unusual will be referred to as an adverse event. Study participants are asked to contact clinic staff immediately if the participants experience a reaction to the topical applications at any time during the study. Expected reactions may be documented in a problem events log. The investigator will use his discretion to remove participants from the study, and all problem events will be reported to Institutional Review Board. Differences in protein expression between the test sites, and after application of test substances for varying periods of time, will be assessed for significance using either Student's t-test or analysis of variance (or non-parametric equivalents, if necessary) depending on the comparison required.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

• Moderate to severe photo-aged skin that is within the Fitzpatrick skin types 1-6
• Must be healthy enough to undergo skin biopsy in the opinion of the investigator
• Must be willing to comply with the requirements of the protocol
• Must have the ability to understand and communicate with the investigator
• Must be able to provide informed consent.

Exclusion Criteria:

• Subjects who are unable to provide informed consent
• Subjects with history of keloid scars
• Subject with significant medical history or current skin diseases that the investigator feels is not safe study participation
• Subjects who have used products containing salicylic acid, beta hydroxyl acids or vitamins A, C, or E in the last 14 days
• Subjects who have used topical antibiotics or topical retinoids in the last 30 days
• Subjects who have had a recent surgical or esthetic procedure in the last 3 months that can affect facial wrinkles or facial hyperpigmentation, such as botulinum toxin injections, chemical peels, laser-based therapies to the face, or face lift surgeries
• Subjects with allergies to lidocaine or epinephrine
• Subjects who self-report as nursing/pregnant or planning to be pregnant during the study

Related Conditions & MeSH terms

• Photoaging of Skin
• Skin Aging
• Skin Diseases

Intervention

Procedure:
• skin biopsy
Skin biopsies will be obtained at different time points.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	Amorepacific Corporation

References & Publications (5)

An S, Cho SY, Kang J, Lee S, Kim HS, Min DJ, Son E, Cho KH. Inhibition of 3-phosphoinositide-dependent protein kinase 1 (PDK1) can revert cellular senescence in human dermal fibroblasts. Proc Natl Acad Sci U S A. 2020 Dec 8;117(49):31535-31546. doi: 10.10 — View Citation

Kim J, Kim HS, Choi DH, Choi J, Cho SY, Kim SH, Baek HS, Yoon KD, Son SW, Son ED, Hong YD, Ko J, Cho SY, Park WS. Kaempferol tetrasaccharides restore skin atrophy via PDK1 inhibition in human skin cells and tissues: Bench and clinical studies. Biomed Phar — View Citation

Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-48. doi: 10.2147/ciia.2006.1.4.327. — View Citation

Pereira AG, Garcia-Perez P, Cassani L, Chamorro F, Cao H, Barba FJ, Simal-Gandara J, Prieto MA. Camellia japonica: A phytochemical perspective and current applications facing its industrial exploitation. Food Chem X. 2022 Feb 17;13:100258. doi: 10.1016/j. — View Citation

Sitohang IBS, Makes WI, Sandora N, Suryanegara J. Topical tretinoin for treating photoaging: A systematic review of randomized controlled trials. Int J Womens Dermatol. 2022 Mar 25;8(1):e003. doi: 10.1097/JW9.0000000000000003. eCollection 2022 Mar. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fibrillin-1 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)	The investigators will detect the fold change of Fibrillin-1 in the basal layer of the epidermis in both skin treated with Red Flavonoids and placebo, by RT-PCR, to determine whether Red Flavonoids can improve skin photodamage and aging.	8 weeks, 16 weeks, 24 weeks
Primary	Collagen type-4 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)	The investigators will detect the fold change of Collagen type-4 in the basal layer of the epidermis in both skin treated with Red Flavonoids and placebo, by RT-PCR, to determine whether Red Flavonoids can improve skin photodamage and aging.	8 weeks, 16 weeks, 24 weeks
Primary	Collagen type-1 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)	The investigators will detect the fold change of Collagen type-1 in the basal layer of the epidermis in both skin treated with Red Flavonoids and placebo, by RT-PCR, to determine whether Red Flavonoids can improve skin photodamage and aging.	8 weeks, 16 weeks, 24 weeks
Primary	Tyrosinase fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)	The investigators will detect the fold change of Tyrosinase in the basal layer of the epidermis in both skin treated with Red Flavonoids and placebo, by RT-PCR, to determine whether Red Flavonoids can improve skin photodamage and aging.	8 weeks, 16 weeks, 24 weeks
Primary	Wrinkles/photoaging as assessed by clinical assessments	Griffith's photonumeric scale will be used. It is a nine-point scale where 0 (zero) is no wrinkles/photodamage and 8 is severe wrinkles/photodamage.	8 weeks, 16 weeks, 24 weeks
Primary	Hydration as assessed by clinical assessments	Skin hydration will be graded with a five-point scale where 0 (zero) is adequate hydration and 4 is severe dehydration.	8 weeks, 16 weeks, 24 weeks
Primary	Loss of elasticity as assessed by clinical assessments	Loss of elasticity will be graded as absent, localized or diffuse.	8 weeks, 16 weeks, 24 weeks
Primary	Brightness as assessed by clinical assessments	Brightness improvement rate will be graded with a five-point scale where 0 (zero) is marked improvement and 4 is no improvement.	8 weeks, 16 weeks, 24 weeks